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Objective: To determine the effects of oxygen fluctuations on pigment epithelial-derived factor (PEDF) and vascular
endothelial growth factor (VEGF)/PEDF ratios in a relevant rat model of retinopathy of prematurity (ROP).
Methods: The expression of retinal PEDF mRNA and of VEGF and PEDF protein were determined using real-time
polymerase chain reaction or enzyme-linked immunosorbent assays at different postnatal day ages for rat pups raised in
room air (RA) or in a rat model mimicking ROP. Statistical outcomes were determined with factorial analyses of variance.
Mean VEGF and PEDF protein levels were determined at different ages for rats in the ROP model and for RA-raised rats,
and the ratio of VEGF/PEDF protein versus age was plotted. At postnatal day (P) 14, inner retinal plexus vascularization
had extended to the ora serrata in pups raised in RA. In the ROP model, avascular retina persisted at P14 and intravitreous
neovascularization developed at P18. Therefore, VEGF and PEDF expression was determined in the ROP model and in
RA-raised rat pups at P14 and P18.
Results: Older age was associated with increased PEDF mRNA (p<0.001), PEDF protein (p=0.005), and VEGF protein
(p=0.005), and VEGF protein (p<0.0001). Exposure to fluctuations of oxygen in the 50/10 oxygen-induced retinopathy
model compared to RA was associated with increased PEDF mRNA (p=0.0185), PEDF protein (p<0.0001), or VEGF
protein (p<0.0001). The VEGF/PEDF ratio favored angiogenic inhibition (<1.0) before but not on P14, when avascular
retina persisted in the ROP model but not in RA. The VEGF/PEDF ratio favored angiogenesis (>1.0) at P14 and P 18
when intravitreous neovascularization occurred in the ROP model.
Conclusions: Increased expression levels of VEGF and PEDF are associated with older postnatal day age or with exposure
to fluctuations in oxygen in the 50/10 oxygen-induced retinopathy model compared to RA. PEDF protein more closely
associates with avascular retinal features and neovascularization than does VEGF protein or the VEGF/PEDF in the ROP
model. Although PEDF has been proposed as a potential treatment in ROP, interventional studies using PEDF in an ROP
model to potentially reduce intravitreous neovascularization are  required  to  determine  timing,  efficacy,  and  dose of
Retinopathy of prematurity (ROP), first reported in 1941
[1], reached epidemic status over the following decades,
blinding many preterm infants. At that time, ROP was
associated with high, unregulated oxygen delivery [2,3].
When inspired oxygen levels were reduced, ROP was
virtually eliminated. Advances in neonatal care and
technology have since led to increased survival of very low
birthweight infants of young gestational age [4] and ROP has
re-emerged [5]. High oxygen at birth is now avoided in
countries that have implemented the technology to monitor
and regulate oxygen and thus may not be a cause of most cases
of ROP [6]. Rather, other factors have been associated with
severe ROP, including poor postnatal weight gain [7] and
oxygen stresses apart from high oxygen at birth, including
fluctuations in transcutaneous oxygen levels [8]. Investigators
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have suggested that lower inspired oxygen concentrations and
perhaps fewer fluctuations in oxygen are associated with the
reduced incidence of ROP [9]. However, a recent large-scale
prospective clinical trial compared 85%–89% oxygen
saturation to 91%–95% oxygen saturation and found the lower
oxygen saturation range to be associated with a reduced
incidence of ROP, but also with increased infant mortality
[10]. Therefore, more detailed investigation is needed
regarding the effects of oxygen levels on severe ROP features
and retinal development in preterm infants. Such knowledge
would also aid in finding therapeutic agents for infant ROP.
Michaelson, Ashton, and Patz [2,3,11] developed a
hypothesis about how severe ROP occurred. It was believed
that high oxygen at birth led to avascular retinal areas that
became hypoxic when infants were weaned to room air (RA).
The retinal hypoxia stimulated the production of an
angiogenic factor or factors [2,3,11]. Of numerous angiogenic
factors studied since the early hypothesis, vascular endothelial
growth factor (VEGF) has been recognized as one of the most
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important in retinal diseases [12]. VEGF is increased in
models of oxygen-induced retinopathy (OIR) with hypoxia-
induced angiogenesis following high constant oxygen-
induced constriction [13] and in human ROP [14]. Excessive
signaling of VEGF through VEGF receptor 2 (VEGFR2) has
been found to disrupt developmental angiogenesis [15].
Conversely, inhibition of VEGF signaling through VEGFR2
has reduced pathologic intravitreous neovascularization
[16-20] without interfering with ongoing retinal vascular
development [16,18,19]. VEGF mRNA was detected in an
infant retina that had severe ROP [21], and infants operated
on for progressive stage 4 ROP had elevated ocular VEGF
protein compared to control infants undergoing congenital
cataract surgery [22]. Finally, intravitreous injections of anti-
VEGF agents have been reported to reduce vascularly active
features, such as intravitreous neovascularization in severe
ROP [23]. However, later retinal detachment has been
reported in some infants treated with anti-VEGF agents [24]
Concerns also exist about using anti-VEGF agents in preterm
infants because VEGF is involved in angiogenesis and
neuroprotection, both important in developing preterm
infants. Therefore, other treatments must be considered.
One such treatment is pigment epithelial-derived factor
(PEDF), which is a potent angiogenic inhibitor [25].
Exogenous administration of PEDF decreased
neovascularization in OIR models of hypoxia-induced
angiogenesis following high constant oxygen-induced
capillary constriction [26,27] or in models of laser-induced
injury [28]. In some studies, decreased levels of PEDF have
been associated with proliferative diabetic retinopathy and
age-related macular degeneration (AMD) [29,30], whereas
increased levels have been shown to reduce morbidity in
neovascular AMD [31]. PEDF is believed to regulate
angiogenesis through multiple mechanisms, including
downregulation of VEGF expression [32]. A ratio of VEGF/
PEDF of less than 1.0 has been associated with reduced
angiogenesis in some models of OIR [33-35]. However, these
models may not reflect the severe ROP that occurs in infants
in neonatal units that monitor and regulate oxygen for preterm
infants. We became interested in PEDF as a potential
treatment in ROP because it is neuroprotective [25] and anti-
inflammatory [36], potentially may regulate VEGF-induced
pathologic angiogenesis, and has been safely tolerated in a
human clinical trial [31].
Much of what has been learned about proposed
mechanisms in ROP has been discovered using models of high
oxygen to induce capillary constriction followed by relative
hypoxia-induced angiogenesis [34,37,38]. These models of
OIR with hypoxia-induced angiogenesis following high
constant oxygen [13] may be relevant to human ROP
described in the 1940s that was associated with high
unregulated oxygen [39]. We use a model developed by John
Penn [40], in which Sprague-Dawley pups and their dams are
placed into a controlled environment where the oxygen
fluctuates between 50% and 10%. The model uses oxygen
levels relevant to ROP in that it yields rat arterial oxygen
concentrations similar to transcutaneous oxygen levels
reported in infants with severe ROP [40]. The model also
produces a characteristic appearance of severe ROP with
peripheral avascular retina similar to zone II ROP [40,41],
followed by retinal tortuosity similar to plus disease [42], and
then intravitreous neovascularization at the junctions of
vascular and avascular retina, similar to stage 3 ROP [41,43].
The model uses fluctuations in oxygen, a risk factor for severe
ROP [8]. Further, abnormalities in photoreceptor and post-
receptor responses in electroretinograms of pups exposed to
this model share similarities with those found in human
preterm infants with severe ROP [44]. For these reasons, the
Penn 50/10 model is described as the ROP model [42]. We
and others have used this model to study the effects of oxygen
and other stresses on the development of severe ROP features
[18,19] and the relationships between features and angiogenic
growth factor signaling pathways [45-49]. In this study, as a
first, step to determine whether PEDF might be a therapeutic
agent to safely prevent severe ROP, we sought to determine
the effect of relevant oxygen levels on the regulation of VEGF
and PEDF in association with severe ROP features using the
Penn rat model of ROP.
METHODS
ROP model: All animal studies were approved by the
University of North Carolina’s Institute for Laboratory
Animal Research (Guide for the Care and Use of Laboratory
Animals) and the University of Utah’s Institute of Animal
Care and Use Committee, and complied with the ARVO
Statement for the Use of Animals in Ophthalmic and Visual
Research. Within 4 h of birth at postnatal day (P) 0, litters of
16 newborn Sprague-Dawley rat pups with their dams
(Charles River, Wilmington, MA) were placed in an
Oxycycler incubator (Biospherix, New York, NY) to cycle
inspired oxygen between 50% oxygen and 10% oxygen every
24 h. Pups from other litters were used to supplement deficient
litters. To maintain the reproducibility of the ROP model,
litters were never depleted below 12 pups. Often, this required
that whole litters be used for individual postnatal day
measurements. After seven cycles of oxygen fluctuations at
P14, pups were then placed into RA for 4 days [40]. Oxygen
levels were monitored daily and recalibrated as needed.
Carbon dioxide in the cage was also monitored daily and was
flushed from the system by maintaining sufficient gas flow
and by adding soda lime, if needed.
We analyzed retinas from pups of several postnatal day
ages preceding and including P14 when full vascularization
of the inner retinal plexus occurred in RA-raised pups, but
persistent avascular retina was present in the ROP model. We
also analyzed pups at P18 when intravitreous
neovascularization occurred in the ROP model. Postnatal day
0 was analyzed as the baseline value. In the ROP model, P8,
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P12, and P14 occurred immediately following a hypoxic
session (10% inspired O2) and P11 and P13 following a
hyperoxic session (50% inspired O2). Following P14, pups
were placed into an RA environment (21% FiO2).
Dissection of retinal tissue for mRNA and protein analyses:
Animals were euthanized with pentobarbital (80 mg/kg
intraperitoneal injection) at the beginning of the change in
inspired oxygen level. Eyes were placed into phosphate
buffered saline (PBS) after the hyaloid vessels and remaining
vitreous were removed. For fresh tissue, retinas were
dissected without ora serratas. The retina was removed from
the eyecup and frozen in modified radioimmunoprecipitation
assay (RIPA) buffer (20 mM Tris base, 120 mM NaCl, 1%
Triton X-100, 0.5% sodium deoxycholate, 0.1% sodium
dodecyl sulfate (SDS), and 10% glycerol) with a protease
inhibitor cocktail (1:100; Sigma, St. Louis, MO) and 1 M
orthovanadate (1:100; Sigma), then stored at −80 °C for
protein or in RNA later (Applied Biosystems, Carlsbad, CA)
for RNA until analysis.
Dissection of retinal tissue for retinal flat mounts: For flat
mounts, following enucleation, eyes were fixed in 2%
paraformaldehyde for 2 h. Retinas were isolated as described
previously [50], but with ora serratas intact, and placed into
PBS after the hyaloid vessels and remaining vitreous were
removed. By making four incisions 90 degrees apart, the
retinas were flattened and then placed onto microscope slides.
Tissue staining and analysis of flat mounts: To stain the
vasculature, the flattened retinas were first permeabilized in
ice-cold 70% v/v ethanol for 20 min, then in PBS/1% Triton
X-100 for 30 min, and then incubated with Alexa Fluor 568
conjugated G. simplicifolia (Bandeiraea) isolectin B4 (5 μg/
ml; Molecular Probes, Carlsbad, CA) in PBS overnight at
4 °C, as previously described [18]. Images of the retinal blood
vessels were captured using a Nikon 80i Research Upright
Microscope, Melville, NY with Surveyor/Turboscan software
and digitally stored for analysis.
Real time quantitative PCR: Total RNA was extracted using
the RNAeasy Mini Kit (Qiagen, Valencia CA). Assays were
performed using the Applied Biosystems 7500 Real-Time
PCR System. Briefly, 1 μg of total RNA was reverse-
transcribed into cDNA using a High Capacity cDNA Kit
(Applied Biosystems), according to the manufacturer’s
protocol. Each TaqMan reaction (16 μl) contained 20 ng of
cDNA, 8 μl of TaqMan PCR MasterMix (Applied
Biosystems) and 1 μM forward primer, 1 μM reverse primer,
and 1 μM probe. Primers were specific for rat (annealing
temperature 60 °C) PEDF: forward 5′-CCA ACT CTT TGC
AGG ACA TG-3′, reverse 5′-TCA CAG GTT TGC CGG
TAA TC-3′, and probe 5′ -ACA GTC CTT GTT TGA GTC
CCC TGA C −3′. Primers and probes were made by UNCs
Oligonucleotide Core Facility. Each sample was run in
duplicate, and each experiment included three non-template
control wells. The 7500 System Software calculates cycle
threshold (Ct) automatically for each well and each value was
normalized to rat β-actin (Actb). Rat Actb was chosen as the
control gene because its expression had previously been found
to be stable under various oxygen stresses. Primers for rat
Actb were forward 5′-TGC CTG ACG GTC AGG TCA-3‘,
reverse 5′-CAG GAA GGA AGG CTG GAA G-3‘, and probe
5′-CAC TAT CGG CAA TGA GCG GTT CCG-3‘. Postnatal
day age 0 indicated retinal tissue harvested within 4 h of birth
and was used in analysis for both the ROP and RA groups.
For graphical representation of PEDF mRNA, this value was
scaled to 1.0 and used as the standard against which fold
changes in mRNA expression were compared. However, for
statistical analysis, raw data were used as described below.
Protein analysis: Retinal samples, which were stored in RIPA
buffer at −80 °C, were thawed, homogenized, and centrifuged
(16,000× g, 10 min, 4 °C). Total protein was quantified with
a Bicinchoninic Acid (BCA) Protein Assay Kit (Bio-Rad,
Hercules, CA, modified from the Lowry assay) [51].
Supernatants were assayed without dilution in duplicate using
commercially available ELISA kits, raised against rat VEGF
(R&D Systems, Rochester MN) or human PEDF
(BioProducts, Middletown, MD). The VEGF ELISA
measures all VEGF splice variants, with the most prevalent
splice variant, VEGF164, representing the greatest percentage
of the ELISA value [52]. The mean minimum detectable dose
for VEGF was 6.4 pg/mL. For the PEDF ELISA, the
manufacturer estimates a 10–50× reduced affinity for rat
PEDF; however, our results met criteria for test validity and
fell within the standard curve. To take into account potential
reduced affinity, we compared retinal values from rat pups in
the 50/10 OIR to rat pups in control RA taken at the same
postnatal day ages.
Calculation of VEGF/PEDF ratios: For each postnatal day
age, the mean values of VEGF or PEDF protein determined
for the ROP model were normalized to the respective mean
RA values of growth factors at the same postnatal day ages.
These normalized values were then used to form a VEGF to
PEDF ratio under the two conditions.
In situ hybridization: Whole eyes were fresh frozen in Optimal
Cutting Temperature (OCT) compound and stored at −80 °C.
Serial 14-µm-thick sections were cut for in situ hybridization,
which was performed at the University of North Carolina’s In
Situ Hybridization Core Facility. Mouse PEDF cDNA [53]
(1374 bp, GenBank AF017055) was kindly supplied by
Joshua Barnett (Vanderbilt University, Nashville, TN).
PEDF cDNA was subcloned into the pBluescript SK vector
(Stratagene, La Jolla, CA) and linearized with HindIII and
XbaI to produce templates for in vitro transcription of
antisense and sense riboprobes. This transcription was
performed using a DIG RNA Labeling Kit (Roche
Diagnostics, Indianapolis, IN) to produce a single stranded
digoxigenin-11-uridine-triphosphate-labeled probe.
Hybridization with a sense strand riboprobe was performed
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under identical conditions to a negative control. A digoxigenin
probe was localized in tissue using an alkaline-phosphatase-
conjugated anti-digoxigenin antibody and visualized using
NBT/BCIP solution (Roche Diagnostics, Mannheim
Germany). PEDF in situ hybridization was imaged using an
Olympus DSU-IX81 spinning disc confocal microscope.
Immunostaining for PEDF: Immunostaining was done using
mouse anti-PEDF (Millipore, Temecula CA) as primary
antibody and visualized using Alexa-Fluor 588-conjugated
goat anti-mouse secondary antibodies (Invitrogen, Carlsbad
CA) using an Olympus (Tokyo, Japan) DSU-IX81 spinning
disc confocal microscope. No primary antibody was used in
the controls.
Statistical analysis: For each postnatal day age, at least five
retinas from different pups taken from at least two different
litters were analyzed. The mean fold changes relative to beta-
actin are graphically represented, with error bars representing
standard errors. While these normalized ratios were used for
graphical representation in the figures, to avoid bias, the raw
data were used for statistical analysis as described below.
Initially, Actb was analyzed by regression analysis of the
ratio of each Actb/VEGF splice variant or PEDF mRNA for
the Ct1 value against respective Actb/VEGF splice variants or
PEDF mRNA for the Ct2 value, and the slope was found to
be indistinguishable from 1.0, the ideal value [54]. The
geometric means of the product of the two ratios were then
determined for each postnatal day age and treatment, and this
was the outcome analyzed. For the analysis of VEGF and
PEDF protein by ELISA, the protein concentration was the
outcome analyzed. A factorial ANOVA with a completely
randomized treatment arrangement was used to determine the
significance of the factors, postnatal day age, and treatment
(RA versus 50/10 OIR model). Post-hoc testing of the
treatment and increasing postnatal day age by treatment
interaction means was accomplished using protected t-tests on
least-squares means, with alpha level adjustment for multiple
comparisons among means accomplished using a method of
simulation [55].
RESULTS
ROP model: Figure 1 shows representative flat mounts of
retinas from an RA-raised pup at P14 (Figure 1C),  and from
pups in the ROP model at P14 (Figure 1A) and P18 (Figure
1B). In the ROP ledom  at P14, avascular  retina comprised
32.8±10.6% of the total retinal area, whereas in RA pups, there
was no avascular retina present [52]. At P18, avascular retina
comprised 23.1±6.2% of the total retina and intravitreous
neovascularization was present in approximately eight clock
hours of all retinas in the ROP model [52], making up
2.29±0.68% of the total retinal area. Numbers are mean±SEM.
PEDF tissue localization: To determine the localization of
PEDF mRNA within the retina of the ROP model, we first
performed in situ hybridization on P14 retinal sections from
pups in the ROP model. At this postnatal day age, retinal
vascularization is restricted to 70%–75% of the retina in the
ROP model [52], as shown in Figure 1. PEDF mRNA was
detected in ganglion cells and cells throughout the inner and
outer nuclear layers (Figure 2). Sense labeled sections of P14
ROP retinas were blank (Figure 2).
We then localized PEDF protein in retinal cryosections
of P14 pups in the ROP model and found labeling in inner and
outer plexiform layers and in the inner nuclear layer. A lower
level of PEDF immunostaining was also seen in the outer
nuclear layer (Figure 2E). Figure 2F shows nonspecific
staining of the secondary antibody.
PEDF mRNA quantification: To quantify the expression of
PEDF mRNA, real time PCR was performed on retinal lysates
of RA-raised pups and those in the ROP model at postnatal
day ages between P0 and P18. The relative PEDF mRNA level
was similar for the P0 and P8 time points and increased from
Figure 1. Retinal flat mounts at P14 and P18 in the ROP model and at P18 in RA samples. Representative lectin-stained flat mounts from rat
pups in the ROP model or RA conditions. In the ROP model, avascular retina remains at P14 (A), while in RA, intraretinal vascularization is
complete at P14 (C). In the ROP model, after seven cycles of oxygen fluctuations by P14, pups are then moved into RA for 4 days. At P18,
intravitreous neovascularization occurs at the junction of vascularized and avascular retina (B).
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P11 to P18 in rats raised in RA (Figure 3). In the ROP model,
retinal PEDF expression was higher compared to RA
counterparts at most time points and appeared to be expressed
to a greater extent than in RA pups at earlier postnatal day
ages. Within the model, the pattern of PEDF mRNA
expression level fluctuated in association with oxygen
concentration in the ROP model. It tended to increase
following hyperoxia at P11 and P13 and decrease following
hypoxia at P8, P12, and P14. Based on statistical analysis,
increased fold expression of PEDF was significantly
associated with older postnatal day age (ANOVA, p=0.0001)
or with the ROP model compared to RA (ANOVA,
p=0.0185). Post-hoc testing revealed only a significantly
increased fold expression in PEDF mRNA at P11 in the ROP
model compared to the RA group (p=0.0017).
PEDF protein concentration in RA and ROP models: PEDF
protein was measured in retinal lysates taken at the same
postnatal day ages as mRNA from rats raised in RA or exposed
to the ROP model. PEDF protein increased with older
postnatal day age in retinas from RA-raised rats (Figure 4).
For rats in the ROP model compared to those raised in RA,
the pattern of PEDF increased before and on P14 when
avascular retina persisted in the ROP model, but not in RA
samples. However, at P18 when neovascularization was
present in the ROP model, the protein levels of PEDF and RA
samples were similar. Compared to that with PEDF mRNA,
the pattern of PEDF protein concentration was less closely
associated with changes in oxygen concentration in the model.
Statistical analysis revealed increased PEDF in association
with older developmental age (ANOVA, p=0.005) or with
exposure to the ROP model compared to RA samples
Figure 2. Tissue labeling of PEDF mRNA and protein in rat ROP model at P14. Sections of P14 rat retina in ROP model labeled by in situ
hybridization for PEDF mRNA showing message in the ganglion cell layer (GCL), and in the inner and outer nuclear layers (INL, ONL; A,
C). Control using sense probe showed no signal (B, D). Immunostaining for PEDF protein in P14 ROP model showed labeling in the inner
and outer plexiform layers and inner and outer nuclear layers (E). No primary control showed nonspecific staining in the ganglion cell layer
(F). Magnification calibration bars are 100 µm (A, B) and 50 µm (C-F).
Figure 3. Quantification of PEDF
mRNA in ROP model at different
postnatal day ages. Real time
polymerase chain reaction values for
PEDF expression in the retina of rat
pups from selected postnatal days (P) 0
through P18 in RA or the ROP model.
Increased PEDF expression associated
with older developmental age
(p=0.0001) or with the ROP model
compared to RA (ANOVA, p=0.0185).
*Post-hoc testing revealed increased
PEDF mRNA at P11 in the ROP model
compared to RA samples (p=0.0017).
Error bars represent standard errors.
Each time point had at least five retinas
from different pups taken from at least
two different litters. mRNA indicates
mRNA.
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(ANOVA, p<0.0001). Based on post-hoc testing, PEDF was
significantly increased in the ROP model compared to RA
samples at P11 and P13, each following a 24 h exposure to
hyperoxia (p=0.0041, p=0.0022, respectively).
VEGF protein concentration in RA samples and in the ROP
model: According to previously published studies, the
VEGF164 isoform is the most prevalent during RA retinal
development and in the ROP model [52,56]. It was also shown
that VEGF mRNA and protein increased with older postnatal
day age and in the ROP model [56]. In agreement with this,
VEGF protein (Figure 5) was significantly increased in
association with older postnatal day age (ANOVA, p<0.0001)
or with exposure to the ROP model compared to RA samples
(ANOVA, p<0.0001). Based on post-hoc testing, there were
significant increases in VEGF protein in the ROP model
compared to RA samples at P8, P12, P14, and P18 (p=0.0002,
p<0.0001, p<0.0001, p=0.0117). In the ROP model, VEGF
was significantly greater following hypoxic compared to
hyperoxic cycles (P12 versus P11 [p=0.0014], P12 versus
P13, and P14 versus P13; p<0.0001, each).
VEGF/PEDF ratios: To compare VEGF and PEDF, we first
developed ratios of the ROP to RA mean retinal protein values
Figure 4. Quantification of PEDF
protein in ROP model at different
postnatal day ages. ELISA
measurements of retinal PEDF protein
from selected postnatal days (P) 0
through P18 in RA or in the ROP model.
Increased PEDF associated with older
developmental age (p=0.005) or the
ROP model compared to RA samples
(ANOVA, p<0.0001). *Post-hoc testing
revealed increased PEDF in the ROP
model compared to RA at P11 and P13
(p=0.0041, p=0.0022 respectively).
Error bars represent standard errors.
Each time point had at least five retinas
from different pups taken from at least
two different litters.
Figure 5. Quantification of VEGF
protein in ROP model at different
postnatal day ages. ELISA
measurements of retinal VEGF protein
from postnatal days (P) 0 through P18 in
RA or the ROP model. Increased VEGF
associated with older developmental
age (ANOVA, p<0.0001) or the ROP
model compared to RA samples
(ANOVA, p<0.0001). Post-hoc testing
revealed increased VEGF protein in the
ROP model compared to RA at P8, P12,
P14, and P18 (p=0.0002, p<.0001,
p<0.0001, p=0.0117). In the ROP
model, VEGF was significantly greater
following hypoxic compared to
hyperoxic cycles (P12 versus P11
[p=0.0014], P12 versus P13, and P14
versus P13; p<0.0001, each). Error bars
represent standard errors. Each
postnatal day age had at least five retinas
from different pups taken from at least
two different litters.
Molecular Vision 2011; 17:1577-1587 <http://www.molvis.org/molvis/v17/a176> © 2011 Molecular Vision
1582
for VEGF and PEDF at each postnatal day age tested. We then
created a ratio between VEGF and PEDF at each postnatal day
age and graphically represented these (Figure 6). This is
similar to methods used in previous reports [35]. At P14,
retinal vascularization of the inner plexus is complete in RA
controls, whereas avascular retina persists in the ROP model
[52] (Figure 1). At P11  and  P13,  the VEGF/PEDF  ratio
favored angiogenic inhibition (ratio less than 1.0). However,
at P14, the VEGF/PEDF protein ratio favored angiogenic
stimulation (greater than 1.0). The ratios were approximately
3.0 at P14 and P18 in the ROP model.
DISCUSSION
Normal development of the retinal vasculature depends on the
integration of several signaling events influenced by a delicate
balance of angiogenic agonists and inhibitors. Of many
factors, two important ones in retinal development are VEGF
[57,58] and PEDF [59]. VEGF is an angiogenic agonist,
upregulated in hypoxia [60], whereas PEDF is an angiogenic
antagonist, upregulated by hyperoxia [59]. Using a model of
ROP, we studied the effects of oxygen stresses, relevant to
preterm infants with ROP, on PEDF expression and the
relative differences in the VEGF/PEDF ratio in comparison
to control rat pups raised in RA. Compared to RA, we found
that retinal PEDF was increased in association with avascular
retina in the ROP model.
The interaction of VEGF and PEDF has been explored in
other models. Oxidative stress increased the angiogenic
potential of cultured RPE cells in association with an
increased fold expression of VEGF to PEDF [33]. Using a
model of high oxygen-induced retinopathy (OIR) in rats, the
fold expression of VEGF was reduced during hyperoxia but
increased during relative hypoxia-induced endothelial
proliferation [35]. Previously, using the ROP model, PEDF
was found to approach levels of that in RA samples at P18
[61], and the VEGF/PEDF ratio favored angiogenesis in
association with the development of intravitreous
neovascularization in the ROP model at P18. We had similar
findings in our study. However, we also studied younger
postnatal day ages before the development of intravitreous
neovascularization at P18. Earlier ages in the model may
relate to the preterm infant retina before the development of
severe ROP. We found that the pattern of the VEGF/PEDF
ratio of retina in the ROP model normalized to RA was similar
to that of VEGF protein, favoring angiogenic stimulation
following a hypoxic cycle (10% O2) and favoring inhibition
following a hyperoxic cycle (50% O2). The VEGF/PEDF
ratio favored angiogenic inhibition before but not at P14,
when avascular retina persisted in the ROP model but
vascularization of the inner plexus was complete in RA pup
retinas. The VEGF/PEDF ratio, PEDF, and VEGF protein
favored angiogenesis at P18 when intravitreous
neovascularization occurred. The PEDF protein level
appeared more closely associated with features of the ROP
model than did VEGF or the VEGF/PEDF ratio.
Most reports that studied young postnatal day ages in
models of OIR did not use relevant animal models such as the
Penn ROP model. Gao et al. [62] examined the effect of high
constant oxygen in rats and found that the ratio of VEGF/
PEDF corresponded to the degree of intravitreous
neovascularization. The investigators also found a difference
according to the strain of rat, in that Brown Norway rats had
more severe neovascularization than did Sprague-Dawley
rats, suggesting a genetic component to oxygen sensitivity.
Based on a verbal communication, no differences in the extent
of intravitreous neovascularization were found between the
two rat strains subjected to oxygen fluctuations. However, it
is not clear what the extremes in inspired oxygen were.
PEDF might be considered as a therapy to prevent severe
ROP in human preterm infants, potentially as an intravitreal
Figure 6. Ratio of VEGF/PEDF protein
in ROP model normalized to RA values.
The ratio of mean VEGF/PEDF in the
ROP model normalized to respective
RA means at selected postnatal day
ages. A ratio >1.0 favors angiogenesis
(P8, P12, P14, P18) and a ratio <1.0
favors angiogenic inhibition (P11 and
P13).
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injection like anti-VEGF agents currently used for adults
[23]. The reasons to consider PEDF are that it inhibits
angiogenesis [27], in part by promoting apoptosis [26,63], it
mitigates inflammation, and it is neuroprotective [64].
Therefore, it would potentially be safer than anti-VEGF
agents. In addition, it was reported that overexpression of
PEDF with an adenovirus associated vector was not shown to
adversely affect the radial expansion of retinal vessels in wild
type mice raised in RA, suggesting that retinal vascular
development can proceed in conditions of overexpressed
PEDF [65]. Additional evidence of potential protective effects
of PEDF was shown in PEDF−/− mice that were found to be
more susceptible to hyperoxia-mediated retinal vascular
constriction and retraction compared to PEDF+/+ mice
subjected to the same conditions. This occurred even though
retinal VEGF protein was increased in PEDF−/− compared to
PEDF+/+ [66]. These data suggest the presence of PEDF may
even benefit the development of intraretinal vascularization,
at least in the condition of high oxygen.
The findings in this manuscript are associations and are
not causative, and further study is warranted to address the
question of whether exogenous PEDF delivered early when
the VEGF/PEDF ratio is less than 1.0 would lead to
persistence of the avascular retina, an unwanted outcome in
ROP. Our findings may be relevant to ROP currently because
the Penn ROP model more closely reflects oxygen levels and
the appearance of ROP in current neonatal units than earlier
models of OIR that were developed to mimic the ROP of the
1940s.
Changes in the patterns of PEDF concentrations based on
the exposure to hypoxia or hyperoxia were best appreciated
in fold expressions of mRNA, and less so in protein. As
anticipated [59], PEDF mRNA was upregulated following
periods of hyperoxia at P11 and P13. The PEDF antibody
recognizes human PEDF but is estimated by the manufacturer
to have a lower affinity for rat PEDF. For this reason, we
normalized mean values of PEDF and VEGF protein to
respective RA means. PEDF protein expression may also be
less sensitive to fluctuating oxygen levels than mRNA
because of the time required for protein translation, post-
translational modification, and possibly sequestration of
growth factors in extracellular matrix.
In summary, we found that compared to RA counterparts,
both VEGF and PEDF were significantly increased in the rat
ROP model at early and late postnatal day ages. However, we
found the relative expression level of VEGF to PEDF protein
favored angiogenic inhibition before but not at P14 when
avascular retina persisted in the model but vascularization of
the inner retinal plexus was complete in RA. Evidence
suggests that PEDF can be released in response to several
stresses and have beneficial effects as a neuroprotectant and
anti-inflammatory agent. Further study is needed to determine
the timing and type of delivery of PEDF in the ROP model.
In this study, the relative expression of PEDF protein was
more closely associated with early features in the ROP model,
i.e., avascular retina, than was the VEGF or the VEGF/PEDF
ratio.
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